Two cases of anaphylaxis due to contrast media during administration of nivolumab and ipilimumab in metastatic renal cell carcinoma.
Kunihisa NezuHiromichi KatayamaAtsushi KyanPublished in: International cancer conference journal (2019)
A combination therapy of nivolumab and ipilimumab is effective for advanced renal cell carcinoma, but there are concerns about immune-related adverse events. A 46-year-old man was hospitalized for metastatic renal cell carcinoma. On day 9, he received nivolumab and ipilimumab. On days 16 and 49, he presented with fever, skin rash, and hypotension after contrast-enhanced computed tomography. A 70-year-old man was hospitalized for metastatic renal cell carcinoma. On day 9, he received nivolumab and ipilimumab. On day 44, he presented with fever, skin rash, and hypotension after contrast-enhanced computed tomography. Both patients were diagnosed with anaphylaxis due to the contrast agent.
Keyphrases
- contrast enhanced
- metastatic renal cell carcinoma
- computed tomography
- diffusion weighted
- magnetic resonance imaging
- combination therapy
- magnetic resonance
- diffusion weighted imaging
- end stage renal disease
- positron emission tomography
- renal cell carcinoma
- dual energy
- chronic kidney disease
- ejection fraction
- newly diagnosed
- wound healing
- prognostic factors
- image quality